Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to “Sell” at ValuEngine

June 27th, 2020 – Comments Off on Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to “Sell” at ValuEngineFiled Under
by

Catalyst Pharmaceuticals Inc logoValuEngine upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong sell rating to a sell rating in a report published on Tuesday, ValuEngine reports.

Several other brokerages have also recently issued reports on CPRX. SunTrust Banks reduced their price objective on Catalyst Pharmaceuticals from $11.00 to $10.00 and set a buy rating on the stock in a research note on Wednesday, May 13th. BidaskClub cut Catalyst Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals currently has an average rating of Buy and an average target price of $8.75.

NASDAQ:CPRX opened at $4.51 on Tuesday. The company has a quick ratio of 6.51, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $4.48 and its two-hundred day moving average is $4.26. Catalyst Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $7.67. The stock has a market capitalization of $476.77 million, a price-to-earnings ratio of 11.28 and a beta of 1.93.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. Catalyst Pharmaceuticals had a return on equity of 52.28% and a net margin of 36.09%. The company had revenue of $29.14 million for the quarter, compared to analysts’ expectations of $31.68 million. On average, sell-side analysts expect that Catalyst Pharmaceuticals will post 0.38 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of CPRX. California Public Employees Retirement System increased its holdings in Catalyst Pharmaceuticals by 49.8% in the fourth quarter. California Public Employees Retirement System now owns 204,129 shares of the biopharmaceutical company’s stock valued at $765,000 after buying an additional 67,876 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $896,000. Victory Capital Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 53.3% during the fourth quarter. Victory Capital Management Inc. now owns 65,449 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 22,745 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Catalyst Pharmaceuticals by 65.4% during the fourth quarter. New York State Common Retirement Fund now owns 160,271 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 63,377 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Catalyst Pharmaceuticals by 3.0% during the fourth quarter. Swiss National Bank now owns 177,300 shares of the biopharmaceutical company’s stock worth $665,000 after purchasing an additional 5,200 shares during the last quarter. 63.69% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Further Reading: How can investors invest in the S&P/TSX Index?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Catalyst Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Read More